Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome - The PRASFIT-ACS study -

Circulation Journal

Volumn 78, Issue 7, 2014, Pages 1684-1692

  Saito, Shigeru ^a   Isshiki, Takaaki ^b   Kimura, Takeshi ^c   Ogawa, Hisao ^d,e   Yokoi, Hiroyoshi ^f,g   Nanto, Shinsuke ^h   Takayama, Morimasa ⁱ   Kitagawa, Kazuo ^h   Nishikawa, Masakatsu ^j   Miyazaki, Shunichi ^k   Nakamura, Masato ^l  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^f FUKUOKA SANNO HOSPITAL   (Japan)

^g INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^h OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ SAKAKIBARA HEART INSTITUTE   (Japan)

^j MIE UNIVERSITY   (Japan)

^k KINKI UNIVERSITY   (Japan)

^l TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

more..

Author keywords

Acute coronary syndrome; Clopidogrel; Major adverse cardiovascular events; Percutaneous coronary intervention; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; JAPAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84903208627     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1482     Document Type: Article

References (14)

1. JJCRAC/Data Center. Report of survey on treatment for cardiovas cular disease 2008 in Japanese. http://www.j-circ.or.jp/jittai_chosa/ jittai_chosa2008web.pdf (accessed July 16, 2010).
2. Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-681.
3. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/ SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
4. Park KW, Kim HS. Options to overcome clopidogrel response variability. Circ J 2012; 76: 287-292.
5. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Braunwald E, Michelson AD, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
6. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
7. Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation: Sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 75: 800-805.
8. Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Basic principle on global clinical trials. September 2007. Tokyo: The Bureau.
9. ICH Steering Committee. Ethnic factors in the acceptability of foreign clinical data (ICH-E5(R1). March 1998.
10. Mauri L, Hsieh WH, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
11. Daida H, Miyauchi K, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, et al. Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: Prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry. Circ J 2013; 77: 934-943.
12. Ruff CT, Giugliano RP, Antman EM, Murphy SA, Lotan C, Heuer H, et al. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol 2012; 155: 424-429.
13. Ehara N, Morimoto T, Furukawa Y, Shizuta S, Taniguchi R, Nakagawa Y, et al. Effect of baseline glycemic level on long-term cardiovascular outcomes after coronary revascularization therapy in patients with type 2 diabetes mellitus treated with hypoglycemic agents. Am J Cardiol 2010; 105: 960-966.
14. Patti G, Proscia C, Di Sciascio G. Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome. Circ J 2013; 78: 33-41.